Objective This collaboration between the American College of Rheumatology and the
American Association of Hip and Knee Surgeons developed an evidence‐based guideline …

Systemic lupus erythematosus (SLE) is a multisystem autoimmune disease of undefined
etiology and with remarkably heterogeneous clinical features. Virtually any organ system …

The past 2 decades have seen a revolution in our approach to therapeutic
immunosuppression. We have moved from relying on broadly active traditional medications …

Lupus nephritis (LN) is a significant complication of systemic lupus erythematosus (SLE),
increasing its morbidity and mortality. Although the current standard of care helps suppress …

The presence of cytosolic double-stranded DNA molecules can trigger multiple innate
immune signalling pathways which converge on the activation of an ER-resident innate …

Objective To identify potential diagnostic markers of lupus nephritis (LN) based on
bioinformatics and machine learning and to explore the significance of immune cell …

Background: Lupus nephritis (LN) is present in over 50% of patients with systemic lupus
erythematosus (SLE) which is managed with immunosuppressive and immunomodulatory …

Systemic lupus erythematosus (SLE) is a chronic autoimmune and inflammatory disorder
with involvement of several organs and systems such as the kidney, lung, brain and the …

The development of biological therapies has had an impact on the management of several
medical conditions. Their use in systemic lupus erythematosus (SLE), however, remains …

Highlights•Current IFN therapy, although commonly used in the clinic, is based on IFN-α and
is highly questionable.•Introduction of IFN-λ would provide a new IFN with specific-cell …